CN101164548A

CN101164548A - Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Info

Publication number: CN101164548A
Application number: CNA2007101850427A
Authority: CN
Inventors: P·菲施曼
Original assignee: Can Fite Biopharma Ltd
Current assignee: Can Fite Biopharma Ltd
Priority date: 1999-09-10
Filing date: 2000-09-08
Publication date: 2008-04-23
Also published as: IL131864A0

Abstract

The invention relates to a medical compound including an adenosine receptors excitant or antagonist, in particular to an excitant combined with A3 adenosine receptors. The invention is used for generating or exuding G-CSF inside an inductor so as to avoid or cure the poisonous side effect of medicines, or to avoid or cure aleukocytosis, in particular to aleukocytosis induced by medicines; and to restrain the growth and proliferation of abnormal cells.

Description

The pharmaceutical composition that comprises adenosine receptor agonist or antagonist

The application is that number of patent application is dividing an application of 008148007 patent application.

Technical field of the present invention

The invention belongs to the field of cancer, with treatment for cancer or to want to eliminate the treatment of the side effect in the treatment of cancer relevant.

Prior art

List some below and describe the relevant prior art of state of arts of the present invention.Boldface type part by following listed document can obtain cited list of references here.

1.Linden?J.The?FASEB?J. 5：2668-2676(1991)；

2.Stiles G.L.Clin.Res. 38：10-18(1990)；

3.Stolfi R.L. waits .Cancer Res. 43: 561-566 (1983);

4.Belardinelli Prog.Cardiovasc.Dis. such as L. 32: 73-97 (1989);

5.Collis?M.G.，Pharmacol.Ther. 41：143-162(1989)；

6.Clark B. and Coupe M.Int.J.Cardiol. 23: 1-10 (1989);

7.Dubey Circulation such as R.K. 96: 2656-2666 (1997)

8.Soderback Clin.Sci. such as U. 81: 691-694 (1994);

9.Gilbertsen?R.B.Agents?actions? 22：91-98(1987)；

10.Bouma .J.Immunol. such as M.G. 153: 4159-4168 (1994);

11.Rozengurt?E.Exp.Cell?Res.139：71-78(1982)；

12.Gonzales F.A., etc., PNAS USA 87: 9717-9721 (1990);

13.Sandberg G. and Fredholm B.B., Thymus 3: 63-75 (1981);

14.Pastan Annu.Rev.Bioche7n. such as I.H. 44: 491-495 (1975);

15.WO?99/02143；

16.Fishman P. waits Cancer Res. 58: 3181-3187 (1998);

17.Djaldetti Cliiz.Eyp.Metastasis such as M. 14: 189-196 (1996);

18.Fishman Cancer Research such as P. 58: 3181-3187 (1998).

Background of the present invention

It is a kind of modal, serious chemotherapy complication that bone marrow is poisoned, and is one of factor of restriction chemotherapeutics dosage.The sickness rate of patient's life danger that it causes and actual mortality rate are higher than other chemotherapy side effect, and can cause the increase of length of stay.In addition, drug-induced bone marrow depression limited a large amount of, to suffering from the administration that malignant tumor patient may more effective chemotherapy dosage.The several method that solves this negative consequence comprises use lithium, prostate E, interferon, lactotransferrin and granulocyte-macrophage flora stimulating factor somatomedin (GM-CSF) and granulocyte-colony stimulating factor somatomedin (G-CSF).Up to the present, somatomedin for example the use of G-CSF be that treatment suffers from a kind of authority's who bites neutrophilic leukocyte cytopenia patient method.It can the hemopoietic predecessor propagation and and differentiation, can also control the functional activity of biting neutrophilic granulocyte and macrophage.But the treatment of G-CSF is very expensive, and, because it is a kind of recombinant cell protein, so it has the side effect of following.

Adenosine is a kind of endogenous purine nucleosides, is prevalent in the mammalian cell.Adenosine is present in blood plasma and other extracellular fluid body medium, and its most physiological effects are brought into play by the receptor of cell surface, are a kind of important adjusting albumen.It is enlivened by metabolism or is subjected to the cell of stress to discharge into extracellular environment.Known it be by with and A1, the A2 G-protein binding relevant with the A3 membrane receptor come onset ^(1-2)The interaction of adenosine and its receptor has caused signal and has oozed out approach, mainly is adenyl cyclase effector system, and it utilizes cAMP as the second message,second messenger.Though suppressed adenyl cyclase with protein bound A1 of Gi and A3 receptor and caused the level of cAMP in the cell to descend, with the protein bound A2 receptor of Gs can activated adenyl cyclase, thereby the level of increase cAMP ⁽³⁾

Owing to almost can find the particular surface receptor of adenosine in all cells, nearly all biological organs system all will be subjected to its local adjusting that discharges to a certain extent.This comprises the adjusting of cardiac electrophysiology character, the adjusting that calmness that neurotransmitters discharge and inhibition and renin discharge and the adjusting of kidney medium vessels anxiety ^(4-7)Adenosine is being brought into play various effects to immune system, comprises by suppressing the anti-inflammatory activity that release of cytokines is brought into play, and suppresses the effect of platelet aggregation, induces the generation of erythropoietin and regulates lymphocyte function ^(8-10)Effect.In addition, find that adenosine also has certain effect in adjusting, wound healing, diuresis and the pain management of some central nervous system (CNS).Prove that also adenosine can induce Normocellular extensive propagation ^(11-14)The regulating action of this cell growth may be that the indirect above-mentioned adenyl cyclase effector system that passes through realizes.

Find adenosine as a kind of chemical protective agent in nearest research, its activity may can stimulate the propagation of medullary cell relevant with it.In addition, find that also adenosine has inhibitory action to tumor cell, this effect obviously suppresses by the G0/G1 cell cycle and reduces telomere signal (telomericsignal) and realize ^(17-18)This dual function makes adenosine become the very attractive imagination of treatment of cancer.

General introduction of the present invention

Can find that according to the present invention adenosine A 3 receptor agonists (A3RAg) has a kind of double effects, they can suppress the propagation of malignant cell on the one hand, and they can offset the toxic and side effects of chemotherapy on the other hand.The A3RAg chemical compound can suppress the propagation and the growth of tumor cell clearly, can reduce tumor load with the drug synergism of antitumor cell toxin, the propagation and the differentiation of medullary cell and leukocyte cell can be induced, and the especially toxic and side effects of chemotherapeutics of other medicines can be offset.And, find also that according to the present invention A3RAg can comprise parenteral administration by a series of form of medication, particularly the form of oral administration is brought into play these activity.Find further that according to the present invention some A3RAg activity can simulate by other the adenosine A 1 or the agonist and the antagonist of A2 receptor: adenosine a1 receptor agonists (A1RAg) is born jointly with A3RAg and is induced the excretory activity of G-CSF; Adenosine A 2 receptor stimulating agents (A2RAg) are born the activity that suppresses malignant cell propagation jointly with A3RAg; And adenosine A 2 receptor antagonists (A2RAn) and A3RAg bear the activity of offsetting poisonous side effect of medicine jointly, for example treatment or prevention leukopenia.

The present invention has related to the application that active component obtains one of following therapeutics/biology effect on its wide significance: the generation or the secretion of inducing G-CSF in the body; The toxic and side effects of prevention or medicine or prevention or treatment leukopenia, especially drug-induced leukopenia; And suppress paracytic growth and propagation.Active component can be adenosine receptor system agonist or the antagonist that A3RAg maybe can produce these therapeutic effect, and this effect is meant the available effect by using A3RAg.

The invention provides some specific embodiments.First embodiment is called as " G-CSF-induces embodiment ", comprises the application of active component, and said active component can be to cause excretory A3RAg of G-CSF or A1Rag in curee's body.Known G-CSF can the hemopoietic archeocyte propagation and differentiation, and can control the functional activity of biting neutrophilic granulocyte and macrophage.Therefore, for example above mentioned these derivants of G-CSF derivant may have very high therapeutics and be worth, for example, and aspect counteracting (promptly prevent, reduce or improve) myelotoxicity.

For being based on the excretory method of G-CSF in a kind of curee's of inducing body, comprise the active component that gives curee's some with this embodiment, this active component comprises the group of uniting formation of A3RAg, A1RAg and A3RAg and A1RAg.

With the corresponding to method that also has another treatment to handle of this embodiment, this method comprises the said active component that gives the required effective dose of curee to reach therapeutical effect, and said therapeutical effect comprises generation or the secretion that lures G-CSF.Further provide the application that said active component is made the excretory pharmaceutical composition of a kind of G-CSF of inducing of a kind of usefulness by this embodiment.Also provide a kind of by this embodiment and be used for inducing in body G-CSF to produce or excretory pharmaceutical composition, said composition comprises the described active component of the effective dose of pharmaceutically useful load.

Embodiment according to another preferred, be called as " leukopenia-prevention embodiment " or clearer and more definite being called here and " bite neutrophilic leukocyte cytopenia-prevention embodiment ", active component is used to by bone marrow the poison prevention or the treatment of the leukopenia cause, said active component can be A3RAg, or A2Ran.

According to this embodiment, the method of a kind of curee's of inducing bone marrow or leukocyte cell proliferation or differentiation can be provided, this method comprises and gives the curee effective amount of actives that this active component is selected from the group of being made up of the coupling of A3RAg, adenosine A 2Ran and A3RAg or A2Ran.Also provide a kind of method of preventing or treating leukopenia by this embodiment, method comprises the said active component that gives the required effective dose of curee.This embodiment further provides a kind of said active component to be used for making a kind of application of inducing the pharmaceutical composition of bone marrow or leukocyte cell proliferation or differentiation.This embodiment also further provides a kind of said active component to be used for making a kind of prevention or has treated the application of the pharmaceutical composition of leukopenia.This pharmaceutical composition can be used to prevention or treatment leukopenia.

According to the specific embodiments that is called as " toxicity prevention embodiment ", above-mentioned active component (be A3RAg or A2Ran, with and in conjunction with the three one of them) be used to offset for example toxic and side effects of chemotherapeutics or nemoleptic medicine of medicine.

Back one embodiment provides a kind of and has been used to prevent or the method for medicine toxic and side effects, and this method comprises and give the curee required effective amount of actives that this active component is selected from by A3RAg, the group of the combination composition of A2RAn and A3RAg and A2Ran.This embodiment also provides a kind of said active component to be used for making to be used to prevents or medicine is induced the application of toxic pharmaceutical composition.This embodiment also further provides a kind of and has been used to prevent or the pharmaceutical composition of medicine toxic and side effects, and said composition comprises said active component and pharmaceutically suitable carrier of effective dose.

As a rule in order to offset drug-induced leukopenia or drug-induced most of toxic and side effects, people wish sometimes to prepare and a kind ofly have such toxic and side effects medicine with the two administration of said active component.Therefore the present invention also provides a kind of pharmaceutical composition, comprises the medicine and the said active component that can cause said toxic and side effects to subject patient in the said composition; The present invention also provides a kind of said active component to be used for making a kind of application of such pharmaceutical composition.The said active component that is included in the said compositions is prevention or the effective dose for the treatment of this toxic and side effects.

According to another embodiment that is called as " propagation-inhibition embodiment ", active component can be used to optionally suppress paracytic growth, for example growth of tumor cell, and said active component can be A3RAg, A2RAg, or the combination of the two.

The method of abnormal cell growth in a kind of curee's of inhibition body can be provided according to this embodiment, this method comprises the active component that gives curee's therapeutic dose, this active component is selected from by A3RAg, the group that the combination of A2Rag and A3RAg and A2Rag is formed.This embodiment also provides a kind of said active component to be used to make a kind of application that suppresses the pharmaceutical composition of abnormal cell growth.This embodiment also further provides a kind of pharmaceutical composition that is used to suppress abnormal cell growth, and said composition comprises said active component and pharmaceutically suitable carrier.

In embodiments of the invention, the active component of administration is wanted the therapeutic effect that reaches dual: suppress paracytic growth and reduce the toxic and side effects of the medicine that can cause this toxic and side effects.

The preferred active component of the present invention is A3RAg.The preferred delivery of active ingredients approach of the present invention is an oral administration.But this preferred route of administration that does not have other active component or active component forecloses.

The dosage of active component especially when wherein active component is A3RAg, preferably is less than 100 μ g/kg body weight, be typically be less than 50 μ g and better be 1-10 μ g/kg body weight.

Detailed description of the present invention

According to the present invention, certain active component, especially adenosine receptor agonist and antagonist can provide new therapeutic use.An embodiment, G-CSF-induces in the embodiment, and some such active component are used to indirect producing and secretion G-CSF from cell.In the another one embodiment, in the toxicity prevention embodiment, some such active component are used to offset the toxic and side effects of medicine such as chemotherapy or nemoleptic medicine.In further embodiment, in leukopenia-prevention embodiment, some such active component are used to offset leukopenia, especially drug-induced leukopenia.Still according to embodiment of the present invention, propagation suppresses embodiment, and some such active component are used to optionally suppress paracytic growth.

The definition of employed here " leukopenia " relates to the minimizing of circulation quantity of leucocyte.Though the feature of leukopenia is to bite neutrophilic granulocyte decreased number (biting the neutrophilic leukocyte cytopenia) in the blood, may also find the decreased number that lymphocyte, mononuclear cell occur, bite acid cell or bite alkaline cell sometimes.

May cause by heritability or congenital diseases by the leukopenia that the generation of biting neutrophilic granulocyte reduces or the separation of excessive spleen produces.Yet leukopenia mainly is observed after treating with medicine, and used medicine such as cell reduce cancer drug, antithyroid medicine, phenothiazine, anticonvulsant, penicillin, sulfanilamide and the chloromycetin of (cytoreductive).The leukopenia that some antineoplastic agents cause is a kind of foreseeable side effect.

Hereinafter, because the drug induced quantity of leucocyte or the minimizing of biting neutrophilic leukocyte quantity will be defined as " drug-induced leukopenia " or " drug-induced neutrocytopenia " at this.And mention cytopenia whenever, should understand that all what be particularly related to is " biting the neutrophilic leukocyte cytopenia ".

In addition, the process that the definition of " prevention of leukopenia and treatment " should be understood to the quantity of leucocyte minimizing is reduced, when if prevention or this type of minimizing have taken place fully, a kind of operation of leukocyte increasing quantity, wherein said quantity of leucocyte reduces otherwise may take place.Leukopenia can show by a series of side effect, is for example increased by some important infectious agent and other infectious agent possibility of infection.The definition of " prevention of leukopenia or treatment " also can be understood as the meaning of improving such parameter of representing the leukopenia result.

Herein pharmaceutically or " effective dose " on the therapeutics may be that factor well known in the prior art decides by some.This amount must effectively reach desirable therapeutic effects, depends on the type and the method for treatment.For those skilled in the art, this amount obviously is the quantity that can effectively improve survival rate, make patient fully recover, make symptom to improve or eliminate fast, or other proper index of person skilled in the art's selection.For example, when said active component is administered for the generation of inducing G-CSF, the effective dose of active component can be the amount that can produce and secrete G-CSF from peripheral blood mononuclear cell, endotheliocyte or fibroblast, G-CSF is manufactured in these cells, for example, stimulate the mature granulocyte predecessor to convert the sophisticated neutrophilic granulocyte of biting to.In the situation that delivery of active ingredients is used for offsetting drug-induced leukopenia, the effective dose of active component can be to make individuality avoid suffering the quantity of leucocyte by drug-induced to reduce, and especially bites the amount of the situation of neutrophilic granulocyte quantity minimizing; Can be that such cell that has reduced is increased, as return to normal level or be higher than the amount of the active component of normal level sometimes; Or the like.In the situation of the toxic and side effects that delivery of active ingredients is used for reduce medicine, the amount of active component can be for example effectively to recover the amount of losing weight that causes owing to medication.In the situation that delivery of active ingredients is used for suppressing abnormal cell growth, as hereinafter describe in detail like that, effective dose can be to suppress such cell proliferation in curee's body and even the amount of elimination tumor.In the situation of the effect that delivery of active ingredients is used for strengthen anticancer chemotherapeutics, effective dose can be to strengthen the toxic amount of cancer specific drug that chemotherapy is handled; Or reach the amount of wanting the effect that reaches but having reduced the amount of required minimizing chemotherapeutics or pharmaceutical composition, promptly reduced the tumor load; Or the like.The embodiment of an effective dose be every day the dosage of A3RAg be less than 100 μ g/kg body weight, be typically and be less than 50 μ g/kg body weight and preferably be less than 10 μ g/kg body weight, for example about 3-6 μ g/kg body weight.Although such daily dose can be divided into sometimes several dosage in one day administration or with the synthetic single dose of several days dosage every several days to patient with a medicine, the situation of especially real slow releasing preparation, but such A3RAg amount is still representational administration every day single dose.

According to the present invention, the preferred A3RAg of active component.A3RAg is a kind of non-selective agonist (any agonist), and it and A3 receptors bind just obtain the A3 receptor activation a kind of therapeutic effect of the present invention then.Should be noted that A3 receptor sometimes also with other receptor such as A1 and A2 acceptor interaction.But, bring into play main effect (promptly can bring into play some secondary role) by the A3 receptor by interacting with other adenosine receptor according to A3RAg used in the present invention.

By embodiment, be that the active component of foundation is a kind of nucleoside derivates with the present invention.Term " nucleoside " means and comprises sugar, preferred ribose or deoxyribose, or any chemical compound of the conjugate that preferably is connected via the N-glycosyl bond of purine or pyrimidine base or sugar and purine or pyrimidine base." nucleoside derivates " be defined in here expression natural nucleoside as hereinbefore defined, synthetic nucleoside or the nucleoside that obtains by insertion, deletion or the outer chemical modification of ring of it being carried out group or modify the derivant that the biological action of wanting is arranged that obtains by conformation with internal ring.

The embodiment of the preferred active component of the present invention is A3RAg.

With embodiment of the present invention is foundation, and active component is the nucleoside derivates shown in the following general formula (I):

R wherein ¹Be C ₁-C ₁₀Alkyl, C ₁-C ₁₀Hydroxy alkyl, C ₁-C ₁₀Carboxyalkyl or C ₁-C ₁₀Group shown in cyano group alkyl or the following general formula (II):

Wherein:

-Y is oxygen, sulfur or carbon atom;

-X ₁Be H, C ₁-C ₁₀Alkyl, R ^aR ^bNC (=O)-or HOR ^c-, R wherein ^aAnd R ^bMay be identical or different group, be selected from hydrogen, C ₁-C ₁₀Alkyl, amino, C ₁-C ₁₀Haloalkyl, C ₁-C ₁₀Aminoalkyl, C ₁-C ₁₀BOC-aminoalkyl and C ₃-C ₁₀Cycloalkyl or be interconnected to form a heterocycle that comprises 2 to 5 carbon atoms, and R ^cBe selected from C ₁-C ₁₀Alkyl, amino, C ₁-C ₁₀Haloalkyl, C ₁-C ₁₀Aminoalkyl, C ₁-C ₁₀BOC-aminoalkyl and C ₃-C ₁₀Cycloalkyl;-X ₂Be H, hydroxyl, C ₁-C ₁₀Alkyl amino, C ₁-C ₁₀Alkyl amido or C ₁-C ₁₀Hydroxy alkyl;

-X ₃And X ₄Be respectively hydrogen, hydroxyl, amino, acylamino-, azido, halogen, alkyl, alkoxyl, carboxyl, nitrilo-, nitro, three fluorine-based, aryl, alkaryl, sulfydryl, thioester, thioether ,-OCOPh ,-OC (=S) OPh or X ₃And X ₄All be to link to each other and form the oxygen or the X of 5 yuan of rings with＞C=S ₂And X ₃Form the ring of molecular formula shown in (III):

Wherein R ' and R " are respectively C ₁-C ₁₀Alkyl;

-R ₂Be selected from hydrogen, halogen, C ₁-C ₁₀Alkyl ether, amino, hydrazide group, C ₁-C ₁₀Alkyl amino, C ₁-C ₁₀Alkoxyl, C ₁-C ₁₀Thio alkoxy, sulfo-pyridine radicals, C ₂-C ₁₀Alkenyl; C ₂-C ₁₀Alkynyl, sulfydryl and C ₁-C ₁₀Alkylthio; And

-R ₃Be-NR ₄R ₅Base, R ₄Be hydrogen or be selected from alkyl, substituted alkyl or aryl-NH-C (Z)-, Z is O, S or NR ^a, R ^aImplication the same,

-and R ₅, at R ₄Be under the situation of hydrogen, R ₅Be selected from substituent group or the cis that replace unsubstituted in one or more positions-and anti-form-1-phenethyl, benzyl, phenethyl or anilides base, said substituent group is selected from C ₁-C ₁₀Alkyl, amino, halogen, C ₁-C ₁₀Haloalkyl, nitro, hydroxyl, acetylamino, C ₁-C ₁₀Alkoxyl and sulfonic acid or their salt; Or R ₄Be benzo two  alkane methyl, furfuryl, L-propyl group alanyl aminobenzene methyl, β-alanyl amino-benzyl, T-BOC-β-alanyl amino-benzyl, phenyl amino, carbamoyl, phenoxy group or C ₁-C ₁₀Cycloalkyl; Or R ₅Be the group of following molecular formula:

Or the suitable salt of chemical compound as defined above, as triethylamine salt; Or work as R ₄Be selected from the alkyl of alkyl, replacement or aryl-NH-C (Z)-group the time, R ₅Be selected from replacement or unsubstituted heteroaryl-NR exactly ^a-C (Z)-, heteroaryl-C (Z)-, alkaryl-NR ^a-C (Z)-, alkaryl-C (Z)-, aryl-NR-C (Z)-and aryl-C (Z)-group; Wherein the definition of Z is the same.

According to this embodiment of the present invention, active component is the nucleoside derivates shown in general formula (IV) preferably:

X wherein ₁, R ₂And R ₄Definition the same.

According to this embodiment preferred active ingredient of the present invention generally speaking for N6-benzyl adenosine-5 '-uronic amide and the derivant of A3-selective adenosine receptor agonist function is arranged.The example of this analog derivative such as N ⁶-2-(4-aminophenyl) ethyl adenosine (APNEA), N ⁶-(4-amino-3-iodobenzene methyl) adenosine-5 '-(N-methyl uronic amide) (AB-MECA) and 1-deoxidation-1-{6-[({3-iodophenyl methyl) amino]-9H-purine-9-yl-N-methyl-β-D-ribofuranose-amide, the latter is also referred to as N in this area ⁶-3-iodobenzene methyl-5 '-methyl carboxamide adenosine, N6-(3-iodobenzene methyl) adenosine-5 '-preamble of N-methyl uronic amide and this paper and hereinafter be abbreviated as the chlorinated derivatives (R of IB-MECA or IB-MECA ₂=Cl), the latter is called as Cl-IB-MECA here, and IB-MECA and Cl-IB-MECA are that the present invention is especially preferred.

According to another embodiment of the invention, active component can be to be commonly referred to as N ⁶-benzyl-adenosine-5 '-alkyl uronic amide-N-oxide or N ⁶-benzyl adenosine-5 '-N-dialkyl group alditol-amide-N ¹The adenosine derivative of-oxide.

Further, active component can be the xanthine shown in the following logical formula V-7-ribonucleotide derivant:

Wherein X is O or S;

R ₆Be R ^aR ^bNC (=0)-or HOP ^c-, wherein

-R ^aAnd R ^bCan be identical or different group, be selected from hydrogen, C ₁-C ₁₀Alkyl, amino, C ₁-C ₁₀Haloalkyl, C ₁-C ₁₀Aminoalkyl and C ₃-C ₁₀Cycloalkyl, or be joined together to form a heterocycle that comprises 2 to 5 carbon atoms; And

-R ^cBe to be selected from C ₁-C ₁₀Alkyl, amino, C ₁-C ₁₀Haloalkyl, C ₁-C ₁₀Aminoalkyl, C ₁-C ₁₀BOC-aminoalkyl and C ₃-C ₁₀Cycloalkyl;

-R ₇And R ₈Can be identical or different group, be selected from alkyl, C ₁-C ₁₀Cycloalkyl, cis-or anti-form-1-phenethyl, unsubstituted benzyl or anilides base and phenyl be substituted the phenyl ether that base replaces in one or more positions, substituent group wherein is selected from C ₁-C ₁₀Alkyl, amino, halogen, C ₁-C ₁₀Haloalkyl, nitro, hydroxyl, acetylamino, C ₁-C ₁₀Alkoxyl and sulfonic acid;

-R ₉Selectable group comprises halogen, benzyl, phenyl, C ₃-C ₁₀Cycloalkyl and C ₁-C ₁₀Alkoxyl;

Or the salt of this chemical compound, as their triethylamine salt.

Part in the chemical compound of above-mentioned definition and their synthetic method see US 5,688,744 for details; US 5,773,423, and US 6,048,865, and WO 95/02604, and WO 99/20284 and WO 99/06053 list these documents here as a reference.

Inducing the active component in the embodiment situation at GSF can be A1Rag.It is a kind of representational adenosine derivative that following molecular formula is arranged

-R ₁Represent rudimentary alkyl, cycloalkyl, preferred C ₃-C ₈Cycloalkyl (comprising that cyclohexyl and the cyclopenta known comprise derivant, are made CPA and CHA by note respectively), cycloalkyl can be substituted, and for example can be replaced by hydroxyl or rudimentary alkyl; R ₁Also can representation hydroxy or hydroxy alkyl; Phenyl, anilid or rudimentary alkane phenyl, all groups can be replaced by one or more substituent groups, as halogen, low alkyl group, haloalkyl such as trifluoro ylmethyl, nitro, cyano group ,-(CH ₂) _mCO ₂R ^a,-(CH ₂) _mCONR ₂R ^aR ^b,-(CH ₂) _mCOR ^a, wherein m represents one from 1 to 6 integer;-SOR ^c,-SO ₂R ^c,-SO ₃H ,-SO ₂NR ^aR ^b,-OR ^a,-SR ^a,-NHSO ₂R ^c,-NHCOR ^a,-NR ^aR ^bOr-NHR ^aCO ₂R ^bWherein

-R ^aAnd R ^bRepresent hydrogen, low alkyl group, alkanoyl, phenyl or naphthyl (latter can by fractional saturation) respectively, alkyl can be substituted or unsubstituted phenyl or phenoxy group arbitrarily replace; Or work as R ₁Representative-NR ^aR ^bThe time, said R ^aAnd R ^bForm 5-or 6-unit heterocycle with nitrogen-atoms, welcome second hetero atom that is selected from oxygen or nitrogen that comprises of this heterocycle, second nitrogen heteroatom wherein can further be replaced by hydrogen or rudimentary alkyl arbitrarily; Or-NR ^aB ^bBe following general formula (VII) or (VIII) shown in group:

Wherein n is one from 1 to 4 a integer;

-Z is hydrogen, rudimentary alkyl or hydroxyl;

-Y is hydrogen, rudimentary alkyl or OR ', and wherein R ' is hydrogen, rudimentary alkyl or rudimentary alkanoyl;

-A is a key or low-grade alkenyl, preferred C1-C4 alkenyl; And

-X and X ' are respectively for example trifluoro ylmethyl, halogen, amino, list-or two-lower alkyl aminos of hydrogen, low alkyl group, lower alkoxy, hydroxyl, low-grade alkane acidyl, nitro, haloalkyl, or are combined into methylene-dioxy as X and X ';

-R ^cRepresent low alkyl group;

R ₂Represent hydrogen, halogen, replacement or unsubstituted low alkyl group or alkenyl, low-grade halogenated alkyl or halogenated alkenyl, cyano group, acetylamino, lower alkoxy, low-grade alkyl amino, NR ^dR ^e, R wherein ^dAnd R ^eBe respectively hydrogen, low alkyl group, phenyl or the phenyl that is replaced by low alkyl group, lower alkoxy, halogen or haloalkyl for example trifluoro ylmethyl or alkoxyl, or-SR ^f, R wherein ^fBe hydrogen, low alkyl group, low-grade alkane acidyl, benzoyl or phenyl;-W representative-OCH ₂-,-NHCH ₂-,-SCH ₂-or-NH (C=O)-;

-R ₃, R ₄And R ₅Represent hydrogen, low alkyl group or low-grade alkenyl, side chain or straight chain C respectively ₁-C ₁₂Alkanoyl, benzoyl or the benzoyl that is replaced by low alkyl group, lower alkoxy, halogen, or R ₄And R ₅Form a five-membered ring, what this five-membered ring can be random is replaced by rudimentary alkyl or alkenyl; R in addition ₃Can also represent phosphate, a hydrogen or dihydrogen orthophosphate or its alkali metal or ammonium or two alkali metal or di-ammonium salts separately;

-R ₆Represent hydrogen, halogen atom or

-a part of R group (is R ₁To R ₆) be that molecular formula is R ^g-SO ₃-R ^h-the sulfo group Hydrocarbon, R wherein ^gThe group of representative is selected from C ₁-C ₁₀Aliphatic compound, phenyl and the low alkyl group that is replaced by aromatic radical can be to replace or unsubstituted aromatic radical R as substituent aromatic radical wherein ^hRepresent a monovalent cation.Suitable monovalent cation comprises lithium, sodium, potassium, ammonium or trialkyl ammonium, and they can dissociate under physiological condition.Remaining R base is hydrogen or halogen atom, unsubstituted Hydrocarbon or other any non-sulfur thing of group as defined above that comprises.

Here employed hydrocarbon chain can be a straight or branched.Especially be noted that definition used herein " alkyl " or " alkenyl " refer to the alkyl or the alkenyl of straight or branched.The definition of " low alkyl group " or " low-grade alkenyl " refers to C respectively ₁-C ₁₀Alkyl or C ₂-C ₁₀Alkenyl, preferred C ₁-C ₆Alkyl and C ₂-C ₆Alkenyl.

Preferred molecular formula is N for the adenosine derivative of (VI) ⁶-UK 80882 (CPA), 2-chloro-CPA (CCPA), and N ⁶-cyclohexyladenosine (CHA) derivant, the preparation of these chemical compounds is well-known for those skilled in the art.The adenosine derivative of other known selection A1 receptor is R wherein ₁Be the chemical compound of anilides base, anilides base wherein can be not replace or replace, for example can by hydroxyl, alkyl, alkoxyl or-CH ₂C (O) R " replace, R wherein " be hydroxyl ,-NHCH ₃,-NHCH ₂CO ₂C ₂H ₅, (ethyl glycine salt), tuloidide (methyl moiety wherein also can be substituted by haloalkyl) or CH ₂C (O) NHC ₆H ₄CH ₂C (O) R , R  wherein represent one can obtain the substituent group of methoxyl group, (for example R  is-NHCH amide substituents ₃), or R  is hydrazides, 1, the 2-diethylamine ,-NHC ₂H ₅NHC (O) CH ₃, 4-(hydroxyl-phenyl) propionyl, biotinylated ethylenediamine or other any suitable Hydrocarbon that can represent above-claimed cpd and A1 agonist.

According to the present invention, be used as the N of active component ⁶-the adenosine derivative that replaces also can be these chemical compounds that contain epoxide moiety, more particularly can be the cycloalkyl epoxy that comprises adenosine derivative (as oxabicyclo or oxatricyclo, the former is as norborny, the latter such as adamantyl).This type of chemical compound of some of them can define with general formula (I),

R wherein ₁Be following general formula (IXa) and (IXb) represented group:

M wherein is a low alkyl group as defined above.

Epoxidation N is arranged ⁶The embodiment of the agonist compound of-norborny comprises interior and exo isomer, can be one of following four kinds of isomers more particularly: outside the 2R-, in the 2R-, outside the 2S-and in the 2S-.

Another one N ⁶The embodiment of-norborny derivant is at purine ring N ¹-position comprises an oxygen atom.This chemical compound is called as N ⁶-(5,6-epoxy norborneol-2-yl) adenosine-1-oxide.

Sometimes, A1RAg can be an adenine derivative, and wherein the β of adenosine-D-ribollranozyl part can be substituted by hydrogen or phenyl.

A2Ran, what can be used according to the present invention is 1,3 shown in the following molecular formula (X), the substituted xanthic 8-styryl derivative of 7-(X):

R wherein ₁And R ₃Be C ₁-C ₄Alkyl, pi-allyl or propargyl

R ₇Be H, methyl or C ₂-C ₈Alkyl

N is 1 to 3

And X is halogen, three fluorine-based alkyl, alkoxyl, hydroxyl, nitro, amino, dialkyl amido, diazonium, isosulfocyanate radical, benzyloxy, aminoalkoxy, alkoxycarbonyl amino, acetoxyl group, acetylamino, succinyl amino, 4-(4-NH ₂-anti--CH ₂CH=CHCH ₂O-3,5-(MeO) ₂, 4-(4-AcNH-is anti--CH ₂CH=CHCH ₂O)-3,5-(MeO) ₂, 4-(uncle 4--BOC-NH-is anti--CH ₂CH=CHCH ₂O)-3,5-(MeO) ₂

Molecular formula for the object lesson of the chemical compound of (X) be (3,7-dimethyl-1 propargyl-xantane).

A2Ran can be the chemical compound shown in the following molecular formula:

Or

As being understanded, the present invention is not limited in above mentioned A3RAg, A2RAg or A2Ran chemical compound.

The chemical compound that with the present invention is foundation can be the as above chemical compound of defined, or also can be its salt or solvate forms, especially its acceptable salt and solvate on the physiology.In addition, when comprising one or more asymmetric carbon atom, active component can comprise isomer and non-corresponding stereoisomer or its mixture of above-mentioned active component.

The pharmaceutically useful salt of above-mentioned active component comprises the salt that these active component and pharmaceutically useful organic acid and mineral acid form.The example of suitable acid comprises nicotinic acid, hydrobromic acid, sulfonic acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic, lactic acid, salicylic acid, succinic acid, p-methyl benzenesulfonic acid, acetic acid citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid and benzenesulfonic acid.

Active component can be used as material (as the prodrug) administration of non-activity, by the processing of its instinct it is further revised and with its activation at curee's specific part then.In some cases, the therapeutics function such as the such pharmaceutical composition of the present invention of derivant is retained.These prodrug also belong to the definition category of employed " active component " here.Equally, the definition of " A3RAg ", " A1RAg ", " A1RAn " " A2Rag " and " A2Ran " also should be understood to include prodrug, though they are precursors, lacks antagonism or antagonistic activity (can be as situation), and they have activity in vivo.

According to the present invention, A3RAg can be by selecting the active similar chemical compound of character and IB-MECA.For example, suppress embodiment according to leukopenia, operable this compounds can according to its stimulate the ability of medullary cell and leukocyte propagation and subsequently its ability of bringing into play effectiveness in vivo select for foundation.For the chemical compound that suppresses in propagation in the embodiment, can suppress the ability of tumor cell proliferation and bring into play this active ability subsequently in vivo and screen according to it.

The activity of A1RAn and A2Ran can be measured, and can carry out necessary modifications with the described and similar method of A3RAg, screens.

Pharmaceutical composition of the present invention can only comprise active component itself, also active component combines with some other composition, wherein said some other composition such as pharmaceutically suitable carrier, diluent, excipient, additive and/or adjuvant, the known composition of some those skilled in the art, the flavoring agent that adds for certain purpose for example, coloring agent, other pharmacy component of lubricant and some.Clearly, pharmaceutically suitable carrier used in the present invention, diluent, excipient, additive be inertia, nontoxic solid or liquid filler normally, diluent or capsule material, preferred not with the material of composition react of the present invention.

In addition, active component also can combine administration with chemotherapeutics, especially in the situation of leukopenia prevention embodiment.Therefore, pharmaceutical composition of the present invention can also comprise a kind of chemotherapeutics except said active component.According to embodiments more of the present invention, said chemotherapeutics is anticancer chemotherapeutics.Should be understood that this term means any one cytotoxic drugs or gives patient's the mixture that contains two or more cytotoxic drugs mixture in order to reduce the patient's tumor lump.

But the present invention finds the oral biological utilisation of A3RAg, can bring into play its dual curative effect (reduce abnormal cell proliferation and prevention or reduce leukopenia) during oral administration.Therefore, according to embodiment preferred, pharmaceutical composition of the present invention is produced and is used for oral administration.This oral component can further comprise pharmaceutically suitable carrier, diluent, excipient, additive or the adjuvant that is applicable to oral administration.

Induce in the embodiment at G-CSF-of the present invention, the pharmaceutical composition that is disclosed is used to increase the G-CSF level from emiocytosis especially.This compounds can be used to promote bite the recovery of neutrophilic leukocyte or suppress paracytic growth after chemotherapy and the bone marrow transplantation.Up to the present, this kind treatment bag carries out the somatomedin administration, and known this Therapeutic Method has some undesired side effect.In addition, well-known, the average cost of G-CSF treatment is very high.

In the category of leukopenia of the present invention prevention embodiment or toxicity prevention embodiment, disclosed pharmaceutical composition is used to improve in the blood circulation leukocytic level or offsets other some toxic and side effects, for example loses weight.This point of the present invention can be used to the various clinical situation.The minimizing that leukocyte is especially bitten neutrophilic granulocyte in the blood circulation can cause the immune system reduction obviously.The example of the immune system reduction that can treat with this point of the present invention is that pre-cancer is recurrent or by drug-induced leukopenia or the drug-induced neutrophilic leukocyte cytopenia of biting.

It is effectively to multiple relevant with abnormal growth of cells of treatment unusually that propagation suppresses embodiment, as cancer, and psoriasis and some autoimmune diseasees.Compositions of the present invention especially can be used for suppressing the propagation of tumor cell, is preferred for anticancer therapy.

When with A3RAg treatment lymph tumor histiocyte, the inhibitory action of these cell proliferation is far away significantly in the inhibitory action with adenosine or ' A1 ' or ' A2 ' agonist, though also can find some activity (referring to illustration 5A) with A2Rag.These results show that tumor cell proliferation inhibition should mainly be attributed to combining of A3RAg and its receptor, but also can be simulated by A2Rag to a certain extent.Therefore, above-mentioned surprising result provides a new therapeutics target for the anticancer cytostatics medicine in future.

In addition, find that further A3RAgs can also effectively suppress the growth of other tumor cell except that lymphoma, as melanoma or colon tumor (referring to illustration 6).Those skilled in the art can clearly predict with suppressing the growth of abnormal division cell can rebuild the advantage that the immune non-specific anticarcinogen of patient is treated the patient by inducing proliferation of bone marrow cells simultaneously.

Fig. 7 A-7B for example, has shown the not same-action of A3RAg.In this specific situation, assessed IB-MECA to tumor and Normocellular effect.Compare with adenosine, the more significant effect of using A3RAg to obtain can more clearly show by these results.When using the A3 receptor antagonist, during MRS-1220, the therapeutic effect of A3RAg is reversible.

Studies confirm that the result of in vitro study in the body; to compare with the result who only with cytotoxic drugs mice is treated with the result that a kind of cytotoxic agent is treated simultaneously to mice with A3RAg, A3RAg shows a kind of chemoproection effect (referring to illustration 8) to mice.In addition, find to descend, shown the chemotherapeutic activity (referring to illustration 9) of A3RAg at the intravital focus number of the mice for the treatment of with A3RAg.Figure 10 A-10B and 19A and 19B, for example, show that leukocyte and the situation of biting neutrophilic granulocyte decline in the peripheral blood appear in the tumor-bearing mice of only treating with cytotoxic drugs, and after chemotherapy, carry out the A3RAg administration, the result who produces is that total white blood cells recovers, and biting neutrophilic granulocyte percent increases.

Therefore, can draw the conclusion that A3RAg has dual curative effect, it can be used as chemotherapeutics, also can be used as chemical protective agent.Obviously, the application of this dual function of A3RAg is also within protection scope of the present invention.

In any case, the administration of pharmaceutical composition of the present invention and dosage should be consistent with good medical practice, consider each patient's clinical setting simultaneously, the position of administration and method, time of administration is arranged, patient's age-sex, body weight and the known factor of some other medical science professional.

Compositions of the present invention can be with the whole bag of tricks administration.Can be taken orally, subcutaneous administration, parenteral administration comprise intravenous administration, intra-arterial administration, the intramuscular administration, and the intraperitoneal administration, or by intranasal administration, and intrathecal drug delivery and the known transfusion administration of this area quantity personnel.

As everyone knows, people's therapeutic process is longer than the therapeutic process of animal usually, the mice that for example exemplifies here.The time of treatment is corresponding with the effectiveness of disease process and active component.Therapeutic scheme was included in several days or the longer time treats with single dose or multiple dose.Patient's kind that treatment time generally accompany disease process process, active component effectiveness and treated.

When compositions of the present invention adopts parenteral administration, generally be made into the injectable form of unit dose (solution, suspension, Emulsion).The pharmaceutical preparation that is suitable for injecting comprises sterile water solution or dispersion liquid and can reformulate the sterile powder of sterile water solution or dispersion liquid.The carrier that can be used as solvent and disperse medium comprises, for example water, ethanol, polyhydric alcohol (as glycerol, propylene glycol, liquid macrogol or the like), its suitably mixture and vegetable oil.

Non-water excipient also can be used as the solvent system of active component, sometimes as Oleum Gossypii semen, Oleum sesami, olive oil, soybean oil, Semen Maydis oil, Oleum helianthi or Oleum Arachidis hypogaeae semen and ester, as isopropyl myristate.

In addition, also can add the various additives of stability, aseptic and the isotonicity that can strengthen compositions, comprise antibiotic antiseptic, antioxidant, chelating agen and buffer agent.The effect of prophylaxis of microbial can be strengthened by various antibacterial agents and antifungal, for example p-Hydroxybenzoate, chlorobutanol, phenol, sorbic acid or the like.

For oral administration, active component can be made into tablet, suspension, solution, Emulsion, capsule, powder, syrup or the like form, and this is that the pharmacist can obtain and use by well-known technology.

The present invention is by the claim definition, and its content is considered to disclose in description, will be described by embodiment and according to accompanying drawing now.Should be understood that employed term is to think it is the original idea rather than the limiting factor of description word as far as possible.

Though the description details of front the specific embodiment of minority of the present invention, but those skilled in the art are understood that, the present invention is not limited to this, may carry out the variation of some other form and details, these change still can not leave scope of the present invention and main idea disclosed herein.

Brief Description Of Drawings

In order to understand the present invention and to understand how reality is implemented, will pass through some non-restrictive example now, according to accompanying drawing, embodiment preferred is described, wherein:

Fig. 1 is the result's of an expression in vitro tests bar diagram, has shown the effect that adenosine in this in vitro tests (Ad), DPCPX (a kind of A1RAn), CPA and CCPA (the two all is A1RAg) or IB-MECA (a kind of A3RAg) produce G-CSF.RPMI with modification handles in contrast with culture.The gained result represents (contrast=100%) with the percent of contrast.

Fig. 2 is that an expression is by [H ³]-thymidine is in conjunction with the bar diagram of the result of the test of test acquisition, this test adds ((+) G-CSFAb light color post) or does not add (the dark post of (-) G-CSFAb-) antibody and come antagonism G-CSF to test with the propagation that adenosine, CPA or IB-MECA stimulate medullary cell.Result of the test has shown the neutralization of anti--g-CSF antibody.The gained result represents (contrast=100%) with the percent of defined contrast.

Fig. 3 A and 3B are that an expression is by [H ³The bar diagram of the result of the test that]-thymidine obtains in conjunction with test exists adenosine, adenosine receptor agonist (Fig. 3 A) or is carrying out proliferation of bone marrow cells during with the bonded adenosine of adenosine receptor antagonists (Fig. 3 B) and test in this test.Receptor stimulating agent test (Fig. 3 A) is CPA (a kind of A1RAg) and IB-MECA (a kind of A3RAg); Receptor antagonist test (Fig. 3 B) is DPCPX (a kind of A1RAn), DMPX (a kind of A2RAn) and MRS (a kind of A3RAn).The gained result is used in the percentage increase of the last bonded thymidine of contrast and represents (contrast=0%).

Fig. 4 represents in vitro tests result's bar diagram, has shown the proliferation of bone marrow cells test of carrying out under the IB-MECA (0.01 μ M, 0.1 μ M and 1.0 μ M) at variable concentrations.The gained result is used in contrast and goes up bonded [H ³]-thymidine percent is represented (contrast=0%).Numeral below the cylindricality is the concentration (μ M) of IB-MECA.

Fig. 5 A and 5B are the bar diagrams of two result of the tests of expression, and the two all carries out in vitro tests, is based on the cell counting test, to adenosine with and antagonist effect that lymphoid tissue oncocyte (Nb2-11C) is grown test.In the test that Fig. 5 A represents, adenosine, CPA (a kind of A1RAg), DMPA (a kind of A2RAg) or IB-MECA (a kind of A3RAg) are tested the effect of lymphoid tissue oncocyte growth.In the test that Fig. 5 B represents, adenosine, DCPX (a kind of A1RAn), DMPX (a kind of A2RAn) or MRS-1220 (a kind of A3RAn) are tested the effect of lymphoid tissue oncocyte growth.The lymphoid tissue oncocyte that to handle with RPMI in contrast.Gained relative comparison as a result is described (contrast=0%) with the percent that suppresses growth.

Fig. 6 is different tumor cell type (B16 melanoma, HTC-116 colon cancer, Nb2-11C lymphoma) the in vitro tests bar diagram of growing state when having A3RAg IB-MECA of expression.The lymphoid tissue oncocyte that to handle with RPMI in contrast.Gained relative comparison as a result is described (contrast=0%) with inhibition percent.

Fig. 7 A and 7B are expression adenosine or A3RAg, the IB-MECA bar diagrams to the in vitro tests of the effect of tumor cell (Nb2-11C lymphoma, Fig. 7 A) or medullary cell (Test Drawing 7B) growth.The result of Fig. 7 A and 7B is respectively compared with the control with suppressing percent and stimulating percent to represent (contrast=0%).

Fig. 8 is illustrated in the bar diagram for the treatment of the in vivo test of periphery leukocyte (WBC) number after 5 days and 9 days with chemotherapeutics (cyclophosphamide).Cyclophosphamide separately (Lycoperdon polymorphum Vitt post) or begin to give chemotherapeutics after 24 hours in conjunction with giving IB-MECA, oral (with the solution of 1ml) administration every day.The mice that to handle with PBS in contrast.The WBC number is represented relative comparison (contrast=0%) with percentage ratio.

Fig. 9 is that expression is to mouse inoculation 2 * 10 ⁵Melanoma cells, combine the bar diagram of carrying out the in vivo test of mouse black-in lymphoma focus number behind the chemotherapeutic treatment with IB-MECA and CHEMO with cyclophosphamide (CHEMO), IB-MECA, A3RAg, in contrast with the phosphoric acid normal saline buffer solution.

Figure 10 A and 10B are the bar diagrams of the in vivo test of expression IB-MECA chemotherapeutic activity.Shown with chemotherapeutics cyclophosphamide (CHEMO) in conjunction with (CHEMO+IB-MECA) or after not in conjunction with the IB-MECA administration, leukocyte (WBC, Figure 10 A) and bite the functional relationship of neutrophilic granulocyte (Figure 10 B) and time.The tumor-bearing mice that to handle with PBS in contrast.Bite the neutrophilic leukocyte number compared with the control and recently represent (contrast=0%) with percentage.

Figure 11 has represented the contrast percentage ratio (not treating mice=100%) in the 7th, the 10 and 14 day nude mice body weight in begin treatment (giving the combination of 5-FU, Cl-IB-MECA or 5-FU and Cl-IB-MECA) back.Treatment comprises that 5-FU administration (black post), 5-FU combine administration (Lycoperdon polymorphum Vitt post) and Cl-IB-MECA individually dosed (white post) with Cl-IB-MECA (a kind of A3RAg).

Figure 12 A and 12B have represented that Cl-IB-MECA is to alleviating the result of the test of the inductive myelotoxic effect of amycin.The ICR mice is adopted in test.Figure 12 A represents leukocyte (WBC) number and Figure 12 B represents the bone marrow cell of nucleation.In Figure 12 A, shown result in two kinds of treatments of four different times, the level of contrast represents with dash line, and in Figure 12 B, shown the therapeutic outcome of two different times, control level is represented with the cylindricality of left-hand side.

Figure 13 has represented mice that anti--G-CSF antibody is treated to control mice, with chemotherapeutics and the several effect of leukocyte (WBC) of the mice treated in conjunction with Cl-IB-MECA with chemotherapeutics, these medicines are oral administration (6 μ g/kg body weight are in 0.2mlPBS).WBC number after injecting anti--G-CSF antibody is represented with light post.All results use the percentage of contrast recently to represent.(contrast=100%).

Figure 14 has represented the development of matched group and treatment group (Cl-IB-MEC oral administration) nude mice tumor size behind injection HCT-116 people colon oncocyte.

Figure 15 has represented the similar result of the test with Figure 14, wherein the size variation of nude mice tumor behind the injection HCT-116 people colon oncocyte is measured.Carried out four groups of tests: matched group, accept the group of 5-FU treatment, the group of Cl-IB-MECA oral administration and accept 5-FU and the group of Cl-IB-MECA therapeutic alliance.

Figure 16 is illustrated in test as described in Figure 15 to have carried out the bar diagram of tumor size after 30 days.

Figure 17 is anti--G-CSF antibody (0-does not have antibody) bar diagram of the inductive proliferation of bone marrow cells result of the test of Cl-IB-MECA of mensuration down of expression variable concentrations (0.05 μ g/ml and 0.5 μ g/ml).Propagation by [ ³H]-thymidine measures in conjunction with testing.

Figure 18 represents to measure the result of the test of the experiment in vitro of B-16 melanoma and proliferation of bone marrow cells.Propagation by [ ³H]-thymidine measures in conjunction with testing.Cellular exposure in 0.01 μ M and 0.1 μ M Cl-IB-MECA in conjunction with (white post) or not in conjunction with (black post) A3RAg-MRS-1523.The gained result explains (contrast=100%) with contrast percent.

Figure 19 A and 19B have represented and the result of the test of Figure 10 A and the similar experiment of 10B, have carried out with Cl-IB-MECA.

Figure 20 has represented to measure the result of the test by the experiment in vitro of IB-MECA or the inductive proliferation of bone marrow cells of Cl-IB-MECA.Two kinds of A3RAg are added in the medullary cell culture with the concentration of 1nM or 10nM, be divided into and add antagonist (Lycoperdon polymorphum Vitt post-" (+) antagonist ") or do not add antagonist (black post-" (-) antagonist ").A kind of A3Ran, MRS-1523, concentration is 10nM.Propagation by [ ³H]-thymidine measures in conjunction with testing.Gained relative comparison is as a result represented (untreated medullary cell contrasts=0% in contrast) with the percent that stimulates.

Result of the test

Tumour cell

Use the tumor cell line (B-16 melanoma and Nb2 11c rat lymthoma) of mouse. B-16 Melanoma cells is by American Type Culture Collection (ATCC), Rockville, Maryland Obtain. Nb2-11C rat lymphoma cell [Pines M.. and Gertler A.J.of Cellular Biochem., 37:119-129 (1988)] by Dr.A.Gertler, Hebrew University, the Israel friendship provides.

Also use colon cancer cell (HCT-116), obtained by ATCC.

Contain 10% hyclone (FBS, Biological Industries, Beit Haemek, Israel) in the RPMI culture medium cell is carried out cellar culture. Cell is carried out biweekly Transfer, it is transferred in the medium of new preparation.

Normal cell

The bone marrow cell that use obtains from the C57BL/6J mouse femur. The preparation of cell as previously mentioned [17].

Medicine/compound

The medicine that uses has: adenosine; Adenosine a1 receptor agonists: CCPA[2-chloro-N⁶-ring penta Base-adenosine], CPA (N-UK 80882); A1RAn:DPCPX (1,3-dipropyl-8-ring The amyl group xanthine); Adenosine A 2 receptor stimulating agents: DMPA (N⁶-[2-(3,5-dimethoxy benzene Base)-and 2-(2-aminomethyl phenyl)-ethyl] adenosine); A2Ran:DMPX (3,7-dimethyl-1-alkynes Propyl group-xantane); A3RAg:IB-MECA (1-deoxidation-1-{6-[({3-iodophenyl } methyl) Amino]-9H-purine-9-yl }-N-methyl-β-D-RIBOSE aldehyde acid amides)), CE-IB-MECA (2-chloro-N⁶-3-iodobenzene methyl)-adenosine-5 '-N-methyl-uronic amide; And gland Glycosides A3 receptor antagonist: MRS-1523 (5-propyl group-2-ethyl-4-propyl group-3-ethylmercapto group carbonyl Base)-6-phenylpyridine 5-carboxylate) and MRS-1200 (9-chloro-2-(2-furyl)-5-[(benzene The base acetyl group) amino] [1,2,4 ,]-triazolyl [1,5-c] quinazoline).

(rabbit anteserum is pure by using column chromatography to carry out albumen to use anti--murine G-CSF antibody Change Cytolab LTD, Weizmann Institute of Science, Israel).

Endoxan is available from Taro medicine Industrial Co., Ltd.. Haifa Bay, Israel.

Mouse

Use 3 months big, average weight is the female ICR of 25gr, the C57BL/6J mouse or (BALB/C blood lineage) mouse. Mouse is buied by the Harlan laboratory, Jerusalem, ISRAEL. Particle food and the running water of standard are provided to mouse.

Embodiment 1: adenosine and adenosine receptor antagonists and agonist are to the effect of G-CSF manufacturing and proliferation of bone marrow cells

In order to verify the hypothesis of adenosine, under the situation that has adenosine or adenosine agonists or antagonist, carry out normal cell and cultivate by stimulating the G-CSF manufacturing to play a role.

For this purpose, the medullary cell from C57BL/6J or the acquisition of ICR mouse femur at first disperses by the probe of 25G.There is being under the situation that adenosine (25 μ M) exists pair cell cultivate with the RPMI culture medium that contains 10% hyclone (FBS) in cell (3 * 10 ' cells/well is in 96 hole microtest plates) then.Adenosine or A1 and A3 adenosine receptor agonist-CPA (a kind of A1RAg, 0.01 μ M), CCPA (a kind of A1RAg, 0.01 μ M), or IB-MECA (a kind of A3RAg, 0.01 μ M) is added in the bone marrow culture under the situation that does not have adenosine to exist; A kind of A1 adenosine receptor antagonists, DPCPX (0.1 μ M) is added in the bone marrow culture under the situation that has adenosine (25 μ M).

With the contrast of the culture that contains RPMI culture medium cell suspension and 5%FBS as above-mentioned test.

With [ ³H]-thymidine is in conjunction with testing the propagation of estimating medullary cell.For this reason, after cultivating 30 hours, every hole is with 1 μ Ci[3H]-thymidine carries out impulse modulation.After cultivating 48 hours, carry out cell harvesting, (NJ USA) measures [3H]-thymidine and absorbs for LKB, Piscataway with liquid scintillation counter.This result of the test as shown in Figure 1, this figure shows that A1RAg or A3RAg have the manufacturing function of G-CSF, this point is similar to the result who obtains with adenosine.

In order to prove that adenosine and agonist thereof can play a role by stimulating G-CSF to make, carried out a further test, in this test, under having adenosine (25 μ M), CPA (0.01 μ M) or IB-MECA (0.01 μ M) situation, will resist-G-CSF antibody (62.5ng/ml) joins in the medullary cell culture.Estimate the cell proliferation situation with aforesaid method.The result of this test as shown in Figure 2, this chart understands that the antibody of G-CSF has suppressed adenosine and agonist thereof the stimulation to proliferation of bone marrow cells.This result shows that having the part activity relevant with the adenosine receptor interaction at least is to bring into play by the manufacturing of G-CSF.

When using A1RAg and A3RAg (CPA and IB-MECA) conjugate, the accumulative total effect of proliferation of bone marrow cells is assessed.The operation of this test is used with the similar test of the experimental result as indicated in Fig. 1 and is finished.After being disperseed, pair cell is cultivated under the situation that has adenosine (25 μ M), CPA (0.01 μ M), IB-MECA (0.01 μ M) or IB-MECA and CPA coupling (concentration separately is 0.01 μ M), is further processed with above-mentioned method then.The gained result as shown in Figure 3A, this chart understands that IB-MECA and the CPA effect of share strengthens.

Adenosine receptor antagonists combines with the conjugate of DMPX (a kind of A2RAn), DPCPX (a kind of A1RAn), MRS-1220 (a kind of A3RAn) or DPCPX and MRS-1220 with adenosine or employing adenosine separately and carries out cell culture the effect of proliferation of bone marrow cells after adopting above-mentioned method in order to compare.The result is shown in Fig. 3 B.Just as can be seen, the A2 receptor also can be caused the increase of proliferation of bone marrow cells by DMPX blocking-up, this effect even the effect when having surpassed independent use adenosine.By comparison, compare with independent use adenosine with the propagation of DPCPX or MRS-1220, its increase has reduced 50%, and DPCPX combines with MRS-1220 and then suppressed propagation fully.

Adopt the IB-MECA (1 μ M, 0.1 μ M or 0.01 μ M) of variable concentrations that aforesaid cell of being anticipated is cultivated.With [H ³]-thymidine stimulates percent in conjunction with test determination.The result as shown in Figure 3, this figure shows that IB-MECA stimulates the propagation of bone marrow in dose-dependent mode.

The side's of enforcement example 2: adenosine and agonist thereof are to the adjusting of growth of tumour cell

Nb2-11C rat lymphoma cell (1.2 * 10 ⁴Individual cell/ml) with 96 hole microtest plates, 1ml contain the RPMI culture medium culturing 48 hours of 5% hyclone.To wherein adding 25 μ M adenosines, 0.01 μ M adenosine receptor agonist (CPA, a kind of A1RAg; DPMA, a kind of A2RAg or IB-MECA, a kind of A3RAg) or with bonded 0.1 μ M adenosine receptor antagonists (DPCPX, a kind of A1RAn of adenosine (25 μ M); DMPX, a kind of A2Ran; Or MRS-1220, a kind of A3RAn).

With the contrast of the culture of the RPMI culture medium cell suspension that contains 5%FBS as above-mentioned test.The cell proliferation degree is measured with the cell counting analysis.

See Fig. 5 A and 5B with the inhibiting comparative result of adenosine.Just as can be seen like this, using IB-MECA, after a kind of A3RAg cultivated, the propagation of Nb2-11C cell was by obvious suppression.Use CPA, do not observing growth inhibited during a kind of A1RAg, using DPMA, during a kind of A2Ran, can find more weak growth inhibited.CPA can not suppress the propagation of these two kinds of tumor cells, shows that adenosine A 1 receptor does not have this activity.But the inhibitory action of DMPA and IB-MECA shows that A2 and A3 adenosine receptor take on certain role respectively in inhibitory action.

In addition, ought have DPCPX as can be seen, a kind of A1RAn does not have effect in essence, and has MRS-1220, and during a kind of A3Ran, adenosine is cancelled basically to the effect of Nb2-11C cell proliferation.DMPA, a kind of A2Ran, but can bring into play accessory still very important effect.The growth that can be drawn tumor cell by these discoveries can be by A3RAg or the effective conclusion that suppresses of A2Ran.

With the method identical with method described above, estimate A3RAg, IB-MECA is to the inhibition of B-16 melanoma, HCT-116 colon tumor and the growth of Nb2-11C lymphoma.The results are shown in Figure 6, represent with the percent that suppresses or breed.

Embodiment 3: adenosine A 3 receptor agonists is to tumor cell and Normocellular not same-action

Use aforesaid test method, checked adenosine, A3RAns and A3RAgs effect growth of tumour cell.

In brief, adenosine is being arranged, or carrying out Nb2-11C lymphoma or medullary cell cultivation under the situation of IB-MECA.The double effects of A3RAg has suppressed the growth of tumor cell when stimulating proliferation of bone marrow cells shown in Fig. 7 A and 7B.

Embodiment 4: research in the body

40 C57BL6/J mices are divided into four groups, all use one of following scheme to handle for every group:

1. matched group: till beginning to be condemned to death from first day of tumor inoculation to mice, every mice intraperitoneal every day (i.p.) injection 1ml normal saline;

2. chemotherapy group: on the one hand at inoculated tumour cell i.p. injection cyclophosphamide after 24 hours, till beginning to be condemned to death from first day of tumor inoculation simultaneously to mice, every mice i.p. every day injection 1ml normal saline;

3. adenosine A 3 receptor agonists (A3RAg) group: till beginning to be condemned to death from that day of tumor inoculation to mice, IB-MECA oral administration every day

4.A3RAg+ chemotherapy group: on the one hand, carry out the IB-MECA oral administration with 3 μ g/kg body weight every day simultaneously at inoculated tumour cell i.p. injection cyclophosphamide after 24 hours

Getting blood the 5th day and the 9th day from the tail vein of mice, is that counting leukocyte (WBC) number obtains blood samples.The result as shown in Figure 8.

In addition, after 18 days, put to death mice, calculate the melanoma tumor focus of its pulmonary.The result as shown in Figure 9.

In order to assess the chemoproection effect of A3RAg, further test again.Mice is treated with cyclophosphamide (the 50mg/kg body weight is in 0.3ml PBS).Giving cytotoxic drugs 48 and after 72 hours, mice is injected adenosine (25 μ g/kg body weight) or IB-MECA (3 or 6 μ g/kg are in 0.2ml PBS) by i.p..The neutrophilic granulocyte number is counted and bitten to check leukocyte (WBC).The result is respectively shown in Figure 10 A (WBCs) and 10B (biting neutrophilic granulocyte).

Just as can be seen, compare with the mice of only treating with IB-MECA, only leukocyte and the number of biting neutrophilic granulocyte descend in the mice peripheral blood for the treatment of with cyclophosphamide.As adenosine or IB-MECA during by administration, the leukocyte sum is resumed, and the latter has very significant effect, recovers fully after 168 hours (7 days).

Embodiment 5: adenosine A 3 receptor agonists prevents that the body weight of the mice treated with chemotherapeutics from reducing

Four groups of nude mices (BALB/C blood lineage),, carry out following processing by 10 every group:

Group 1: the mice of not treating [request is confirmed].

Group 2: continuous 5 days intraperitoneal (i.p.) of mice injection 5-fluoro-uracil (5-FU, the 30mg/kg body weight is in PBS)

Group 3: the same i.p. injection of mice 5-FU with second group, but be since second day, every other day give the oral Cl-IB-MECA of mice (the 6ug/kg body weight is in 0.2mlPBS) later on.

Group 4: mice is as above accepted the Cl-IB-MECA administration.

Measured the weight of mice at the 7th, 10 and 14 day, the result as shown in figure 11.

Just as can be seen, compared with the control, 5-FU has tangible effect to mice weight, when Cl-IB-MECA combines administration with 5-FU, can partly prevent the reduction of its weight.Cl-IB-MECA itself can not cause weight loss in essence.This test shows that the A3 adenosine receptor agonist has comprehensive protective effect to some poisonous effects of chemotherapy.

Embodiment 6:Cl-IB-MECA protection mice is not subjected to the bone marrow toxicity effect ICR mice of chemotherapeutics amycin to treat (i.p. injection, 10mg/kg is in 0.5ml PBS) with amycin.After the cytotoxic drugs administration 24,48 and 72 hours, Cl-IB-MECA (6 μ g/kg body weight) mice oral administration.At 72 hours, 96 hours, 120 hours and 144 hours, mice is put to death blood sampling.In addition, draw bone marrow, after preparation being dyeed, the preparation of drawing is carried out to the cell counting of nucleus with Coumassile indigo plant from the femur of mice.

Test with three groups of mices:

Group 1:(contrast) mice is only used the PBS administration.

Group 2: mice is only treated with amycin.

Group 3: and above equally carry out the amycin administration, the while is in conjunction with the Cl-IB-MECA administration.

Numeration of leukocyte the results are shown in Figure 12A, and bone marrow karyoblast count results is seen Figure 12 B.These results show that clearly when the Cl-IB-MECA administration, peripheral leukocytes number and bone marrow karyoblast number all have significant increase.This is the protective effect that A3RAg obviously has the bone marrow toxicity effect of antagonism amycin

Embodiment 7: in the anti-G-CSF antibody and the bone marrow protective effect of Cl-IB-MECA

The ICR mice is divided into following six groups:

Group 1: matched group-only carry out excipient administration.

Group 2: regulate with anti--G-CSF antibody (5 μ g/ mice).

Group 3: chemotherapy group-carry out cyclophosphamide (CYP-50mg/kg body weight) administration.

Group 4: chemotherapy (50mg/kg body weight CYP)+anti--G-CSF antibody (5 μ g/ mice).

Group 5: chemotherapy (50mg/kg body weight CYP)+Cl-IB-MECA (6 μ g/kg body weight)+anti--G-CSF antibody (5 μ g/ mice)

Group 6: chemotherapy (50mg/kg body weight CYP)+Cl-IB-MECA (6 μ g/kg body weight)+anti--G-CSF antibody (5 μ g/ mice)

Every group has 10 mices, and test repeats twice.

CYP is a peritoneal injection, uses 0.2ml PBS as carrier.

After the cyclophosphamide administration 48 and 72 hours, Cl-IB-MECA oral administration (using 0.2ml PBS).

After the chemotherapeutics administration 72 hours, anti--the quiet notes administration of G-CSF antibody (using 0.2ml PBS).

At chemotherapy blood sample collection after 124 hours.Determine leukocyte (WBC) number with the Coulter enumerator, use by the tablet preparation that is coated with of May-Grundvald-Giemsa solution-dyed and finish different cell countings.

The WBC count results is seen Figure 13.Can find that only the mice with the cyclophosphamide treatment shows the decline of peripheral blood WBC number.In group with Cl-IB-MECA treatment, WBC number and bite the group (not showing the transfer result who bites neutrophilic granulocyte) that neutrophilic granulocyte percent is significantly higher than chemotherapeutic treatment.When will resist-when G-CSF antibody gives matched group or chemotherapy group, can observe the decline of the WBC number of expection.With the mice that anti--G-CSF antibody uses chemotherapeutics and Cl-IB-MECA to treat, can eliminate the protective effect of Cl-IB-MECA, this point can clearly as can be seen from Figure 13 be come.Can draw Cl-IB-MECA by these results is to promote the conclusion that G-CSF produces and excretory activity is brought into play by Cl-IB-MECA to immune protective effect.

Embodiment 8:Cl-IB-MECA suppresses the growth of HCT-116 human colon carcinoma in the nude mouse

By to nude mice (BALB/C blood lineage) subcutaneous injection 1 * 10 ⁶HCT-116 human colon carcinoma disease cell formation tumor (Harlan, Jerusalem, Israel).Every other day, the Cl-IB-MECA (using 0.2mlPBS) of the oral 6 μ g/kg body weight of mice treats.The mice of only using excipient (PBS) to treat.Every group has 10 mices.Measure growth of tumor speed by biweekly measuring the orthogonal diameter of each tumor, according to formula π/6[D ₁D ₂Estimate the size of tumor.The results are shown in Figure 14.Can see that the treatment group has significant inhibition to tumor growth.

Independently test Cl-IB-MECA and 5-fluorouracil (5-FU) combined treatment are tested with an other cover.With 1X1O ⁶The HCT-116 cell is given mouse bare subcutaneous injection.After one day, peritoneal injection 5-FU (the 30mg/kg body weight is used 0.2ml PBS) carried out 4 days subsequently more continuously.Every other day, mice is with the oral Cl-IB-MECA of 5 μ g/kg body weight (using 0.2ml PBS).The mice of will be only treating with excipient (PBS) or 5-FU in contrast.Every group of 10 mices.Measure growth of tumor speed by biweekly measuring the orthogonal diameter of each tumor, according to formula π/6[D ₁D ₂] estimate the size of tumor.

The results are shown in Figure 15 and 16.Can observe and use 5-FU, the growth of tumor of Cl-IB-MECA and Cl-IB-MECA and 5-FU combined treatment all is suppressed significantly.After 20 days, can be clearly seen that Cl-IB-MECA and 5-FU synergism, especially as shown in figure 16 (Figure 16 representative be the 30th day result) by the quality of noting tumor.

Embodiment 9:Cl-IB-MECA stimulates proliferation of bone marrow cells by inducing G-CSF to produce

In 96 hole microtest plates to medullary cell (3 * 10 ⁶Cell/ml) cultivate.To wherein adding the Cl-IB-MECA that final concentration is 10nM, wherein containing or do not contain final concentration is the anti-G-CSF-antibody of 0.05 and 0.5 μ g/ml.With [ ³H]-thymidine is in conjunction with the test determination cell proliferation.The result as shown in figure 17.

Can see that anti--G-CSF antibody suppresses proliferation of bone marrow cells in dose-dependent mode.This experiment shows that also the activity of Cl-IB-MECA is brought into play by G-CSF approach (comprising that G-CSF secretes from cell).

Embodiment 10:Cl-IB-MECA suppresses growth of tumour cell and stimulates proliferation of bone marrow cells and differentiation

In 96 hole microtest plates, carry out B-16 melanoma cells (5 * 10 ⁵Cell/ml) and medullary cell (3 * 10 ⁶Cell/ml) cultivate.Culture is with 10%FTS RPMI culture medium as a supplement.To wherein adding the Cl-IB-MECA that final concentration is 0.01 μ M or 0.1 μ M, wherein contain or do not contain adenosine A 3 receptor antagonist, MRS-1523.With aforementioned [ ³H]-thymidine is in conjunction with the test determination cell proliferation.The result as shown in figure 18.Can see that when having MRS-1523 to exist, the propagation of B-16 melanoma cells and medullary cell does not change compared with the control.In contrast, Cl-IB-MECA has brought into play the effect that suppresses B-16 melanoma cells propagation and stimulate medullary cell.

These results have shown the dual function of A3 adenosine receptor agonist.

Embodiment 11:CI-IB-MECA is as chemical protective agent

Carry out embodiment similar to Example 4 with Cl-IB-MECA, the results are shown in Figure 19A and 19B, this figure has proved the chemoproection activity of Cl-IB-MECA.

Embodiment 12:IB-MECA and Cl-IB-MECA are to the effect of proliferation of bone marrow cells

Cultivate the medullary cell of Mus with aforesaid method.Existing or do not have A3RAn, under the situation of MRS-1523, is 1 or IB-MECA or the Cl-IB-MECA of 10nM to wherein adding concentration.Concentration with 10nM adds antagonist.The result as shown in figure 20.

Can see that by Figure 20 the effect of IB-MECA and Cl-IB-MECA all is a dose dependent.In addition, can also see that this acting on to a great extent can be suppressed by A3Ran.

Claims

1. effective amount of actives reaches the purposes of the pharmaceutical composition of a certain therapeutic effect in preparation, described curative effect comprises that selectivity suppresses and the relevant abnormal cell hypertrophy of needs treatment patient's autoimmune disease, wherein this active component is an A3 selective adenosine A3 receptor stimulating agent (A3RAg), this agonist is brought into play it by described adenosine A 3 receptor and is mainly acted on, described amount is less than 100 μ g/kg body weight, and

Wherein said active component is the nucleoside derivates shown in a kind of following general formula (I):

Wherein:

-Y is oxygen, sulfur or CH ₂

-X ₁Be H, C ₁-C ₁₀Alkyl, R ^aR ^bNC (=O)-or HOR ^c-, R wherein ^aAnd R ^bMay be identical or different group, be selected from hydrogen, C ₁-C ₁₀Alkyl, amino, C ₁-C ₁₀Haloalkyl, C ₁-C ₁₀Aminoalkyl, C ₁-C ₁₀BOC-aminoalkyl and C ₃-C ₁₀Cycloalkyl or be interconnected to form a heterocycle that comprises 2 to 5 carbon atoms, and R ^cBe to be selected from C ₁-C ₁₀Alkyl, amino, C ₁-C ₁₀Haloalkyl, C ₁-C ₁₀Aminoalkyl, C ₁-C ₁₀BOC-aminoalkyl and C ₃-C ₁₀Cycloalkyl;

-X ₂Be H, hydroxyl, C ₁-C ₁₀Alkyl amino, C ₁-C ₁₀Alkyl amido or C ₁-C ₁₀Hydroxy alkyl;

Wherein R ' and R " are respectively C ₁-C ₁₀Alkyl;

-R ₂Be selected from hydrogen, halogen, C ₁-C ₁₀Alkyl ether, amino, hydrazide group, C ₁-C ₁₀Alkyl amino, C ₁-C ₁₀Alkoxyl, C ₁-C ₁₀Thio alkoxy, sulfo-pyridine radicals, C ₂-C ₁₀Alkenyl; C ₂-C ₁₀Alkynyl, sulfydryl and C ₁-C ₁₀The alkyl sulfenyl; And

-R ₃Be-NR ₄R ₅Base, R ₄Be hydrogen or be selected from alkyl, substituted alkyl or aryl-NH-C (Z)-,, Z is O, S or NR ^a, R ^aImplication the same,

Work as R ₄Be be selected from the alkyl of alkyl, replacement or aryl-NH-C (Z)-group the time, R ₅Be selected from replacement or unsubstituted heteroaryl-NR exactly ^a-C (Z)-, heteroaryl-C (Z)-, alkaryl-NR ^a-C (Z)-, alkaryl-C (Z)-, aryl-NR-C (Z)-and aryl-C (Z)-Ji;

Wherein the definition of Z is the same;

Or the suitable salt of chemical compound as defined above.

2. purposes as claimed in claim 1, wherein said active component is the A3 selectivity A3RAg that the nucleoside derivates shown in the following general formula (IV) is represented:

X wherein ₁, R ₂And R ₅Definition the same with in the claim 1.

3. purposes as claimed in claim 2, wherein said active component is N ⁶-benzyl adenosine-5 '-uronic amide.

4. purposes as claimed in claim 2, wherein said active component is selected from N ⁶-2-(4-aminophenyl) ethyl adenosine (APNEA), N ⁶-(4-amino-3-iodobenzene methyl) adenosine-5 '-(N-methyl uronic amide) (AB-MECA) and 1-deoxidation-1-{6-[({3-iodophenyl methyl) amino]-9H-purine-9-yl-N-methyl-β-D-ribofuranose aldehyde-amide (IB-MECA) and 2-chloro-N ⁶-(2-iodobenzene methyl)-adenosine 5 '-N-methyl-uronic amide (Cl-IB-MECA).

5. purposes as claimed in claim 2, wherein said active component is a kind of A3 selectivity A3RAg that is selected from the nucleoside derivates shown in the general formula (IV), wherein

X ₁Be R ^aR ^bNC (=O)-, R wherein ^aAnd R ^bMay be identical or different group, be selected from hydrogen, C ₁-C ₁₀Alkyl, amino, C ₁-C ₁₀Haloalkyl, C ₁-C ₁₀Aminoalkyl and C ₃-C ₁₀Cycloalkyl;

-R ₂Be selected from hydrogen, halogen, C ₁-C ₁₀Alkoxyl, amino, C ₂-C ₁₀Alkenyl and C ₂-C ₁₀Alkynyl; And

-R ₄Be selected from R-and S-1-phenylethyl, not substituted benzyl and-individual or a plurality of positions are selected from C ₁-C ₁₀Alkyl, amino, halogen, C ₁-C ₁₀Haloalkyl, nitro, hydroxyl, acetylamino, C ₁-C ₁₀The benzyl that the substituent group of alkoxyl and sulfo group replaces.

6. purposes as claimed in claim 2, wherein said active component is for being selected from those A3 selectivity A3RAg of formula (IV), wherein

R ^aAnd R ^bIdentical or different, be selected from hydrogen or C ₁-C ₁₀Alkyl; R ₂Be hydrogen or halogen;

R ^aBe hydrogen, R ₂Be hydrogen, R ₅It is unsubstituted benzyl;

R ^bBe C ₁-C ₁₀Alkyl or C ₃-C ₁₀Cycloalkyl, R ₅Be R-or S-1-phenylethyl or be selected from halogen, amino, acetylamino, C in one or more positions ₁-C ₁₀The benzyl that the substituent group of haloalkyl and sulfo group replaces, wherein said sulfonic derivative is a salt;

R ₂Be formula R ^dThe C of-C=C- ₂-C ₁₀Alkynyl; Or

R ₂Be halogen, C ₁-C ₁₀Alkylamino or C ₁-C ₁₀Alkylthio group, R ^aBe hydrogen, R ^bBe C ₁-C ₁₀Alkyl, R ₅It is unsubstituted benzyl.

7. as each purposes of claim 1-6, wherein said active component is the A3 selectivity A3RAg of triethyl ammonium salt form.

8. as each purposes of claim 1-7, the amount of wherein said A3RAg is like this, and it is brought into play it by the A3 adenosine receptor and mainly acts on, and does not activate the adenosine receptor outside the A3 adenosine receptor basically.

9. as each purposes of claim 1-8, wherein said drug composition oral administration.

10. as each purposes of claim 1-9, wherein said amount is less than 50 μ g/kg body weight.